The phase III trial of Liang et al. [1] on the optimal chemotherapy regimen for concurrent chemoradiation in patients with inoperable stage III NSCLC is of interest as it contradicts, in part, previously published data. Surprisingly, the study revealed a survival advantage for etoposide/cisplatin (EP) (administered every 4 weeks) over paclitaxel/carboplatin (PC) weekly concurrent chemoradiation and did not confirm results from the previous Veterans Affairs Central Cancer Registry analysis [2]. Despite a relatively high rate of stage IIIB disease and low rate of complete remission, favorable 2- and 3-year overall survival was achieved.

中文翻译：

---

不能手术的III期NSCLC患者的依托泊苷/顺铂相对于紫杉醇/卡铂同时放化疗的生存优势：对ECOG 2患者的亚组分析将引起广泛关注

Liang等人的III期试验。[1]关于不能手术的III期NSCLC患者同时放化疗的最佳化疗方案是令人感兴趣的，因为它部分与先前发表的数据相矛盾。出乎意料的是，该研究显示依托泊苷/顺铂（EP）（每4周给药）比每周紫杉醇/卡铂（PC）同时放化疗具有生存优势，并且未证实以前的退伍军人事务中心癌症登记处分析的结果[2]。尽管IIIB期疾病的发生率相对较高，完全缓解率较低，但仍实现了良好的2年和3年总生存率。